12 Best Genomics Stocks To Buy Now

Published on December 10, 2023 at 11:59 am by Ramish Cheema in Hedge Funds, News

In this piece, we will take a look at the 12 best genomics stocks to buy now. If you want to skip our introduction to the genomics industry and all the latest trends, then take a look at 5 Best Genomics Stocks To Buy Now.

If there’s one thing that can be said with certainty it’s that the ability to transform materials has contributed significantly to humanity’s progress. Whether it’s burning wood to generate power, converting water into steam, building jet engines, or manufacturing semiconductors, manipulating matter enables humans to create new products and advance civilization as a whole.

The advent of the coronavirus pandemic introduced a new technology in the public sphere through coronavirus vaccines, The technology, called Messenger Ribonucleic Acid (MRNA), is a specialized variant of RNA – one of the building blocks of the human body. It enables the body to produce antigens that fight viruses and became the latest example of matter manipulation delivering breakthrough results.

Along with RNA, the broader study of manipulating human genes is called genomics. Genes are the code on which a human body is built and they determine features such as height, eye color, and hair fall. Research shows that the global genomics industry was worth $27.58 billion in 2021 and it is expected to grow at a compounded annual growth rate (CAGR) of 18.2% between 2022 and 2026 to be worth $63.5 billion by the end of the forecast period. This growth is expected to be fueled through government spending, as genomics starts to offer hope for treating painfully debilitating and often deadly diseases such as cancer.

Looking at this, you might be wondering what exactly genomics seeks to do. Well, the area primarily concerns itself with components of the human body that are called nucleases. A nuclease is a biological entity that is involved in repairing damage to the human DNA. It is essentially a protein called an enzyme, and genomics primarily works with three nucleases. These are zinc-finger nucleases (ZFN), transcription activator-like effector nucleases (TALEN), and the clustered regularly interspaced short palindromic repeats-associated protein 9 (CRISPR-Cas9). For more details, you can check out the Top 20 Genomics Companies in the World.

Shifting gears to take a look at what’s happening in the genomics industry these days, players are making key moves in important areas. For instance, Pleasanton, California-based genomics firm 10x Genomics, Inc. (NASDAQ:TXG) shared in November 2023 that it has teamed up with a global database of genomics research to help discover and develop new treatments for cancers and tumors. 10x Genomics provides companies with products that help with genomic mapping, and its transcriptomics platform will be used for analyzing patient reactions to treatments.

Another firm that made the news recently is Verve Therapeutics, Inc. (NASDAQ:VERV). Verv is based in America’s biotechnolgoy hub Massachussetts, and it is developing gene based medicines for heart disorders. The firm announced results from a trial of its gene editing medicine for high cholesterol which showed that a single dose of the drug led to as much as a 55% reduction in cholesterol. However, after the results were announced, Verve’s shares tanked by 41% on the market, as investors chose to focus on two heart attacks within the trial patient cohort – one of which ended up being fatal.

Finally, before we head to our list of the best genomics stocks to buy, some recent comments from the management of Illumina, Inc. (NASDAQ:ILMN) are worth noting:

. . .in Q3, Illumina delivered revenue of approximately $1.12 billion, flat year-over-year, or up 1% on a constant currency basis.

This was a disappointing result. The macroeconomic environment remains challenging for our industry and for our customers, with customers increasingly cautious and constrained in their purchasing decisions. Despite a lower gross margin year-over-year, tight management of our operating expenses allowed us to deliver diluted non-GAAP EPS of $0.33, also approximately flat year-over-year. While we cannot control external environment, Illumina’s management team and I remain focused on supporting our customers and our own operational execution. Part of my comprehensive review of the business includes reexamining our strategic initiatives and our targets for long-term revenue growth and operating margins. We will lay out our new targets for you later next year.

With these details in mind, let’s take a look at some top genomics stocks, with the notable ones being Illumina, Inc. (NASDAQ:ILMN), Natera, Inc. (NASDAQ:NTRA), and Pacific Biosciences of California, Inc. (NASDAQ:PACB).

Vlad Teodor/Shutterstock.com

Our Methodology

To make our list of the best genomics stocks to buy, we ranked all companies that directly or indirectly participate in the industry by the number of hedge funds that had bought their shares during Q3 2023. Out of these, the top genomics stocks are as follows.

Best Genomics Stocks To Buy Now

12. Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

Number of Hedge Fund Investors In Q3 2023: 20

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) is an American biotechnology company headquartered in Cambridge, Massachusetts. The firm scored a win in November when it teamed up with a dairy company to develop environmentally friendly products.

During Q3 2023, 20 out of the 910 hedge funds part of Insider Monkey’s database had held a stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA). It joins Natera, Inc. (NASDAQ:NTRA),Illumina, Inc. (NASDAQ:ILMN), and Pacific Biosciences of California, Inc. (NASDAQ:PACB) in our list of the best genomics stocks to buy.

11. Editas Medicine, Inc. (NASDAQ:EDIT)

Number of Hedge Fund Investors In Q3 2023: 21

Editas Medicine, Inc. (NASDAQ:EDIT) is a pure play genomics firm that uses CRISPR to develop treatments for sickle cell disease and cancer. The firm has beaten analyst EPS estimates in three out of its four latest quarters and the stock is rated Buy on average.

After digging through 910 hedge funds for their third quarter of 2023 shareholdings, Insider Monkey found that 21 had invested in the company. David Kroin’s Deep Track Capital was Editas Medicine, Inc. (NASDAQ:EDIT)’s biggest shareholder as it owned $55.3 million worth of shares.

10. Krystal Biotech, Inc. (NASDAQ:KRYS)

Number of Hedge Fund Investors In Q3 2023: 22

Krystal Biotech, Inc. (NASDAQ:KRYS) is developing gene based therapies for diseases such as cystic fibrosis. It is one of the best rated stocks on our list, since not only the shares are rated Strong Buy on average but the average share price target of $152 prices in a rough $50 upside.

By the end of this year’s September quarter, 22 out of the 910 hedge funds polled by Insider Monkey had bought and owned Krystal Biotech, Inc. (NASDAQ:KRYS)’s shares. Kurt Von Emster’s VenBio Select Advisor owned the largest stake which was worth $297 million.

9. CRISPR Therapeutics AG (NASDAQ:CRSP)

Number of Hedge Fund Investors In Q3 2023: 24

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the best known genomic companies in the world whose CRISPR platform is synonymous with the industry. These days the firm is reorienting its therapeutic portfolio to focus away from cancer to immune system diseases.

Insider Monkey took a look at 910 hedge funds for their third quarter of 2023 shareholdings and found that 24 had invested in the company. CRISPR Therapeutics AG (NASDAQ:CRSP)’s biggest hedge fund investor is Catherine D. Wood’s ARK Investment Management as it owns 7.1 million shares that are worth $325 million.

8. Blueprint Medicines Corporation (NASDAQ:BPMC)

Number of Hedge Fund Investors In Q3 2023: 25

Blueprint Medicines Corporation (NASDAQ:BPMC) is developing treatments for cancers of the lung, thyroid, and gastrointestinal system. The firm scored a win in October 2023 when Oppenheimer upgraded its shares to Outperform from Perform.

As of September 2023 end, 25 out of the 910 hedge funds profiled by Insider Monkey had held a stake in Blueprint Medicines Corporation (NASDAQ:BPMC). Kris Jenner, Gordon Bussard, Graham Mcphail’s Rock Springs Capital Management was the largest shareholder due to its $134 million stake.

7. uniQure N.V. (NASDAQ:QURE)

Number of Hedge Fund Investors In Q3 2023: 26

uniQure N.V. (NASDAQ:QURE) is a Dutch gene therapy company focusing on treatments for sclerosis, Huntington’s disease, epilepsy, and other ailments. It’s another highly rated genomics stock, having garnered an average share rating of Strong Buy and an average share price target of $32.08.

After digging through 910 hedge fund portfolios for this year’s third quarter, Insider Monkey found that 26 had bought and owned the firm’s shares. uniQure N.V. (NASDAQ:QURE)’s biggest hedge fund investor is Wilmot B. Harkey and Daniel Mack’s Nantahala Capital Management due to its $20.2 million investment.

6. 10x Genomics, Inc. (NASDAQ:TXG)

Number of Hedge Fund Investors In Q3 2023: 26

10x Genomics, Inc. (NASDAQ:TXG) is an American biotechnology company that sells equipment to the genomics industry. The firm hasn’t been doing well on the financial front as of late since it has missed analyst EPS estimates in three out of its four latest quarters.

26 out of the 910 hedge funds part of Insider Monkey’s Q3 2023 database had invested in 10x Genomics, Inc. (NASDAQ:TXG). Catherine D. Wood’s ARK Investment Management owned a $123 million stake which made it the firm’s largest shareholder.

Illumina, Inc. (NASDAQ:ILMN), Natera, Inc. (NASDAQ:NTRA), 10x Genomics, Inc. (NASDAQ:TXG), and Pacific Biosciences of California, Inc. (NASDAQ:PACB) are some top genomics stocks with hedge fund interest.

Click here to continue reading and check out 5 Best Genomics Stocks To Buy Now.

AI Fire Sale: Insider Monkey’s #1 AI Stock Pick Is On A Steep Discount

Published on May 1, 2024 at by Inan Dogan, PhD

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

The whispers are turning into roars.

Artificial intelligence isn’t science fiction anymore.

It’s the revolution reshaping every industry on the planet.

From driverless cars to medical breakthroughs, AI is on the cusp of a global explosion, and savvy investors stand to reap the rewards.

Here’s why this is the prime moment to jump on the AI bandwagon:

Exponential Growth on the Horizon: Forget linear growth – AI is poised for a hockey stick trajectory.

Imagine every sector, from healthcare to finance, infused with superhuman intelligence.

We’re talking disease prediction, hyper-personalized marketing, and automated logistics that streamline everything.

This isn’t a maybe – it’s an inevitability.

Early investors will be the ones positioned to ride the wave of this technological tsunami.

Ground Floor Opportunity: Remember the early days of the internet?

Those who saw the potential of tech giants back then are sitting pretty today.

AI is at a similar inflection point.

We’re not talking about established players – we’re talking about nimble startups with groundbreaking ideas and the potential to become the next Google or Amazon.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 10,000% Return: This AI Stock is a Diamond in the Rough (But Our Help is Key!)

The AI revolution is upon us, and savvy investors stand to make a fortune.

But with so many choices, how do you find the hidden gem – the company poised for explosive growth?

That’s where our expertise comes in.

We’ve got the answer, but there’s a twist…

Imagine an AI company so groundbreaking, so far ahead of the curve, that even if its stock price quadrupled today, it would still be considered ridiculously cheap.

That’s the potential you’re looking at. This isn’t just about a decent return – we’re talking about a 10,000% gain over the next decade!

Our research team has identified a hidden gem – an AI company with cutting-edge technology, massive potential, and a current stock price that screams opportunity.

This company boasts the most advanced technology in the AI sector, putting them leagues ahead of competitors.

It’s like having a race car on a go-kart track.

They have a strong possibility of cornering entire markets, becoming the undisputed leader in their field.

Here’s the catch (it’s a good one): To uncover this sleeping giant, you’ll need our exclusive intel.

We want to make sure none of our valued readers miss out on this groundbreaking opportunity!

That’s why we’re slashing the price of our Premium Readership Newsletter by a whopping 75%.

For a ridiculously low price of just $24, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single restaurant meal!

Here’s why this is a deal you can’t afford to pass up:

The Name of the Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.
Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.
Lifetime Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund ANYTIME, no questions asked.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

Head over to our website and subscribe to our Premium Readership Newsletter for just $24.
Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.
Sit back, relax, and know that you’re backed by our ironclad lifetime money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Subscribe Now!

A New Dawn is Coming to U.S. Stocks

Published on May 2, 2024 at by Insider Monkey Staff

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…

Insider Monkey Ads

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Log In

Sign Up